All GLG News Analyses Filed Under: Infectious Disease
Posted May 5, 2008
Ricin Vaccine Market Relies on Threat of Terror
Analysis of: DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Ricin Vaccine Market Relies on Threat of Terror
Analysis of: DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Ricin is an extraordinarily potent toxin that is fatal because of its ability to inhibit protein synthesis and rapidly cause multisystem failure. Because ricin can be prepared from castro beans, it has the potential to be used in terrorist attacks. The present vaccine has the potential to...
Posted May 5, 2008
Can biologic drugs tackle antibiotic resistance?
Analysis of: Can biologic drugs tackle antibiotic resistance? | www.pharmaceutical-business-review.com
Author: GLG Member Program Contributor
Analysis of: Can biologic drugs tackle antibiotic resistance? | www.pharmaceutical-business-review.com
Author: GLG Member Program Contributor
Immunomodulation especially with antibodies is difficult. Proteins are not as easily given and distributed through the body as low molecular weight compounds. I believe that the first drug to be effective will pave the way for many others
Posted April 14, 2008
FDA Clears Glaxo Diarrhea - Virus Vaccine
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Member Program Contributor
The key to success of marketing Rotarix or similar Rotavirus vaccines is in the design of clinical trials and evaluation of criteria and results of past use of these vaccines in developing countries that have a high incidence of rotavirus diarrhea in infants. Rotavirus vaccine use...
Posted April 14, 2008
Cubist Finds Its Antibiotic Cubicin Is Tainted
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: GLG Member Program Contributor
ReadyMED® is a infusion device used primarily in outpatient settings for administering antiobiotics in the home. ReadyMED® requires little patient or caregiver training and works by gravity. No IV poles or pumps...
Posted April 14, 2008Cubist's Antibiotic Cubicin is Tainted: A Mess Not of Their Doing? Maybe, Maybe Not.
Analysis of: Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
Author: Eric Gruff, Principal E4 Consulting
The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has leeched out of the Cardinal Health ReadyMED drug pumps that are used for delivering Cubicin. Regardless of who is at fault, everyone involved (Cubist,...
Posted April 7, 2008
FDA Clears Glaxo Diarrhea - Virus Vaccine
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Member Program Contributor
Analysis of: FDA Clears Glaxo Diarrhea - Virus Vaccine | www.nytimes.com
Author: GLG Member Program Contributor
-Glaxo's Rotarix vaccine was approved last week for prevention of rotavirus infection in infants -Merck's product, Rotateq, on the market for 2 years in the US, already has an established pipeline to essentially all pediatric primary care providers -There are small differences between the 2 vaccines,...
Posted April 4, 2008
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
This article fails to explain how Lipsovir will prevent breakouts of new lesions. They say that early use of the ointment in an episode will shorten the duration about 1 1/2 days but where is the evidence that it prevent new episodes? Also there is a lot of viral resistance to acyclovir,...
Posted March 31, 2008
Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
Analysis of: Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels | www.pipelinereview.com
Author: GLG Member Program Contributor
This drug in the form of a patch will solve one problem of vaccination for the Pandemic Flu; that is the two-step process. It also may have impact on the autistic concerns associated with immunizations that are administered containing small amounts of mercury.
Posted March 31, 2008
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
The article published in the www.pharmalive.com is presenting a very useful information for preventing common illness, such as cold sores. The successful clinical outcome from phase III trial for Lipsovir is a progressive step for Medivir to develop preventative medicine. Particularly, the combination...
Posted March 28, 2008
Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment
Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
Previous
Page :
1 2 3 4 5 6 7 8 9 10 11 Next11 to
20
of 210Analysis of: Medivir: Lipsovir Prevents Cold Sores - Phase III Clinical Trial Results First to Show Prevention by Early Treatment | pharmalive.com
Author: GLG Member Program Contributor
Many patients wish to rid themselves of recurrent cold sores. If this cream really works, there will be a market for it.
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Doctors Say Medication Is Overused in Dementia
www.nytimes.com
Medicare fees to doctors fall Tuesday
news.yahoo.com
Why anaesthetics can make the pain worse
www.newscientist.com
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
www.investor.jnj.com
FDA Panel To Weigh Heart Trials For Diabetes Meds
www.pharmalot.com
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Obesity: Higher Healthcare Costs, Lower Productivity
June 26, 2008
Best acne care product I've seen.
June 25, 2008
Jeff is in accounting not a healthcare provider.
June 23, 2008
A bit misdirected?
June 20, 2008

